Video

Results of phase 3 PADRES trial of neoadjuvant axitinib in renal cell carcinoma

Author(s):

Urology Times staff
Conference|AUA
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Lead author Kevin Hakimi discusses the background and results of the study, “Interim analysis of PADRES (prior axitinib as a determinant of outcome of renal surgery NCT03438708) clinical trial,” which he presented at the 2022 AUA Annual Meeting (LBA01-08).

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      Subscribe Now!
      Related Videos
      Jad Chahoud, MD, on the phase 1b STELLAR-002 trial in ccRCC
      Jad Chahoud, MD, on the phase 1b STELLAR-002 trial in ccRCC
      Jens Bedke, MD, on efficacy of EV plus pembrolizumab across subgroups in la/mUC
      Jens Bedke, MD, on efficacy of EV plus pembrolizumab across subgroups in la/mUC
      Professor Dickon Hayne shares data on mitomycin plus BCG in high-risk NMIBC
      Professor Dickon Hayne shares data on mitomycin plus BCG in high-risk NMIBC
      Thomas Powles, MBBS, MRCP, MD, on efficacy of sasanlimab plus BCG in BCG-naïve NMIBC
      Thomas Powles, MBBS, MRCP, MD, on efficacy of sasanlimab plus BCG in BCG-naïve NMIBC
      Andrew Armstrong, MD, shares 5-year data on enzalutamide plus ADT in mHSPC
      Andrew Armstrong, MD, shares 5-year data on enzalutamide plus ADT in mHSPC
      Professor Dickon Hayne on bladder cancer data to watch for at ASCO 2025
      Professor Dickon Hayne on bladder cancer data to watch for at ASCO 2025
      Andrew Armstrong, MD, previews key prostate cancer data at ASCO 2025
      Andrew Armstrong, MD, previews key prostate cancer data at ASCO 2025
      5 key trial insights from AUA 2025
      5 key trial insights from AUA 2025
      Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
      Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
      Khurshid Ghani, MD, on trial of stent omission following ureteroscopy
      Khurshid Ghani, MD, on trial of stent omission following ureteroscopy
      Related Content
      Second-line cabozantinib shows efficacy in advanced renal cell carcinoma
      June 9th 2025

      Second-line cabozantinib shows efficacy in advanced renal cell carcinoma

      Hannah Clarke
      The regimen showed activity regardless of the prior immunotherapy-based combination used in the first-line setting.
      Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
      May 4th 2025

      Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

      Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
      Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
      Data supports mitomycin plus BCG as alternative to BCG alone in NMIBC
      June 5th 2025

      Data supports mitomycin plus BCG as alternative to BCG alone in NMIBC

      Hannah Clarke
      According to the authors, the mitomycin/BCG regimen could alleviate some of the burden of the global BCG shortage.
      Pearls & Perspectives: Evolving role of APPs in urology, with Corinna Hughes, DNP, at AUA 2025
      May 1st 2025

      Pearls & Perspectives: Evolving role of APPs in urology, with Corinna Hughes, DNP, at AUA 2025

      Amy M. Pearlman, MD
      Corinna Hughes, DNP, sits down with Amy Pearlman, MD, to discuss the evolving recognition of APPs in urology.
      Amy L. Shaver, PhD, PharmD, MPH
      June 5th 2025

      GLP-1 agonist use is rising in men with prostate cancer

      Benjamin P. Saylor
      In 2015, 1245 patients had prostate cancer and had also initiated a GLP-1 or GIP/GLP-1 receptor agonist compared with 69,808 patients in 2024.
      Adding niraparib to AAP extends rPFS in HRR-positive mCSPC
      June 4th 2025

      Adding niraparib to AAP extends rPFS in HRR-positive mCSPC

      Hannah Clarke
      “AMPLITUDE supports early genomic testing and niraparib plus AAP as a new treatment option for patients with mCSPC and HRR gene alterations," the authors wrote.
      © 2025 MJH Life Sciences

      All rights reserved.